ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

OVID Ovid Therapeutics Inc

3.34
0.00 (0.00%)
Pre Mercado
Última actualización: 03:09:41
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Ovid Therapeutics Inc OVID NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 3.34 03:09:41
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.34
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
04/4/202407:00GLOBEOvid Therapeutics to Present at the 23rd Annual Needham..
08/3/202407:24EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/3/202407:20EDGAR2Form 8-K - Current report
08/3/202407:00GLOBEOvid Therapeutics Reports Business Updates, Fourth Quarter..
28/2/202407:00GLOBEOvid Therapeutics to Present at the TD Cowen 44th Annual..
26/2/202417:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202417:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202416:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202416:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202410:10EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202405:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202407:00GLOBEOvid Therapeutics to Present at the Oppenheimer 34th Annual..
06/12/202316:08EDGAR2Form 8-K - Current report
01/12/202306:30GLOBEOvid Therapeutics to Present Five Abstracts Supporting its..
15/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
15/11/202315:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/11/202315:08EDGAR2Form S-3 - Registration statement under Securities Act of..
03/11/202307:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202307:10EDGAR2Form 8-K - Current report
03/11/202307:00GLOBEOvid Therapeutics Reports Third Quarter 2023 Financial..
18/10/202307:04EDGAR2Form 8-K - Current report
18/10/202307:00GLOBEOvid Therapeutics and Ligand Pharmaceuticals Enter into a..
10/10/202307:00GLOBEOvid Therapeutics to Present at the Jefferies Biotech..
02/10/202311:15EDGAR2Form 8-K - Current report
26/9/202306:30GLOBEOvid Therapeutics to Host Investor Event - R&D Day on..
20/9/202306:30GLOBEOvid Therapeutics to Present at the 2023 Cantor Fitzgerald..
30/8/202307:00GLOBEOvid Therapeutics to Participate in Upcoming September..
04/8/202308:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/8/202308:10EDGAR2Form 8-K - Current report
04/8/202307:00GLOBEOvid Therapeutics Reports Second Quarter 2023 Financial..
01/8/202307:00GLOBEOvid Therapeutics to Present at the BTIG Virtual..
31/7/202316:21EDGAR2Form SC 13G - Statement of acquisition of beneficial..
28/6/202307:00GLOBEOvid Therapeutics Expands Its Scientific Leadership Team &..
26/6/202307:00GLOBEOvid Therapeutics Added to Russell 3000® Index
05/5/202306:30GLOBEOvid Therapeutics Reports First Quarter 2023 Financial..
01/5/202305:00GLOBEOvid Therapeutics Announces Collaboration with Graviton..

Su Consulta Reciente

Delayed Upgrade Clock